AIDS Research and Treatment [137] O. Pontesilli, M. R. Klein, S. R. Kerkhof-Garde et al., “Longi- tudinal analysis of human immunodeﬁciency virus type 1- speciﬁc cytotoxic T lymphocyte responses: a predominant gag-speciﬁc response is associated with nonprogressive infec- tion,” Journal of Infectious Diseases, vol. 178, no. 4, pp. 1008– 1018, 1998. [138] M. R. Betts, M. C. Nason, S. M. West et al., “HIV nonprogres- sors preferentially maintain highly functional HIV-speciﬁc CD8+ T cells,” Blood, vol. 107, no. 12, pp. 4781–4789, 2006. [139] P. Jagannathan, C. M. Osborne, C. Royce et al., “Compar- isons of CD8+ T cells speciﬁc for human immunodeﬁciency virus, hepatitis C virus, and cytomegalovirus reveal dif- ferences in frequency, immunodominance, phenotype, and interleukin-2 responsiveness,” Journal of Virology, vol. 83, no. 6, pp. 2728–2742, 2009. [140] A. Peris-Pertusa, M. Lopez, N. I. Rallon, C. Restrepo, V. Soriano, and J. M. Benito, “Evolution of the functional proﬁle of HIV-speciﬁc CD8+ T cells in patients with diﬀerent pro- gression of HIV infection over 4 years,” Journal of Acquired Immune Deﬁciency Syndromes, vol. 55, no. 1, pp. 29–38, 2010. [141] D. E. Kaufmann, D. G. Kavanagh, F. Pereyra et al., “Upreg- ulation of CTLA-4 by HIV-speciﬁc CD4+ T cells correlates with disease progression and deﬁnes a reversible immune dysfunction,” Nature Immunology, vol. 8, no. 11, pp. 1246– 1254, 2007. [142] S. A. Migueles, C. M. Osborne, C. Royce et al., “Lytic granule loading of CD8+ T cells is required for HIV-infected cell elimination associated with immune control,” Immunity, vol. 29, no. 6, pp. 1009–1021, 2008. [143] L. Verkoczy, G. Kelsoe, M. A. Moody, and B. F. Haynes, “Role of immune mechanisms in induction of HIV-1 broadly neutralizing antibodies,” Current Opinion in Immunology, vol. 23, no. 3, pp. 383–390, 2011. [144] N. A. Doria-Rose, R. M. Klein, M. G. Daniels et al., “Breadth of human immunodeﬁciency virus-speciﬁc neutralizing activity in sera: clustering analysis and association with clinical variables,” Journal of Virology, vol. 84, no. 3, pp. 1631– 1636, 2010. [145] M. M. Sajadi, Y. Guan, A. L. DeVico et al., “Correlation between circulating HIV-1 RNA and broad HIV-1 neutraliz- ing antibody activity,” Journal of Acquired Immune Deﬁciency Syndromes, vol. 57, no. 1, pp. 9–15, 2011. [146] O. Lambotte, G. Ferrari, C. Moog et al., “Heterogeneous neu- tralizing antibody and antibody-dependent cell cytotoxicity responses in HIV-1 elite controllers,” AIDS, vol. 23, no. 8, pp. 897–906, 2009. [147] M. Mahalanabis, P. Jayaraman, T. Miura et al., “Continu- ous viral escape and selection by autologous neutralizing antibodies in drug-na¨ıve human immunodeﬁciency virus controllers,” Journal of Virology, vol. 83, no. 2, pp. 662–672, 2009. [148] H. Yamamoto, M. Kawada, T. Tsukamoto et al., “Vaccine- based, long-term, stable control of simian/human immun- odeﬁciency virus 89.6PD replication in rhesus macaques,” Journal of General Virology, vol. 88, no. 2, pp. 652–659, 2007. [149] S. K. Choudhary, N. Vrisekoop, C. A. Jansen et al., “Low immune activation despite high levels of pathogenic human immunodeﬁciency virus type 1 results in long-term asymp- tomatic disease,” Journal of Virology, vol. 81, no. 16, pp. 8838– 8842, 2007. [150] P. W. Hunt, H. Hatano, E. Sinclair et al., “HIV-speciﬁc CD4+ T cells may contribute to viral persistence in HIV 13 controllers,” Clinical Infectious Diseases, vol. 52, no. 5, pp. 681–687, 2011. [151] N. Chomont, M. El-Far, P. Ancuta et al., “HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation,” Nature Medicine, vol. 15, no. 8, pp. 893–900, 2009. [152] T. W. Chun, L. Carruth, D. Finzi et al., “Quantiﬁcation of latent tissue reservoirs and total body viral load in HIV-1 infection,” Nature, vol. 387, no. 6629, pp. 183–188, 1997. [153] T. W. Chun, D. C. Nickle, J. S. Justement et al., “Persistence of HIV in gut-associated lymphoid tissue despite long-term antiretroviral therapy,” Journal of Infectious Diseases, vol. 197, no. 5, pp. 714–720, 2008. [154] J. M. Brenchley, D. A. Price, T. W. Schacker et al., “Microbial translocation is a cause of systemic immune activation in chronic HIV infection,” Nature Medicine, vol. 12, no. 12, pp. 1365–1371, 2006. [155] E. H. Graf, A. M. Mexas, J. J. Yu et al., “Elite suppressors harbor low levels of integrated HIV DNA and high levels of 2-LTR circular HIV DNA compared to HIV+ patients on and oﬀ HAART,” PLoS Pathogens, vol. 7, no. 2, Article ID e1001300, 2011. [156] A. Sa´ez-Cirio´ n, C. Hamimi, A. Bergamaschi et al., “Restric- tion of HIV-1 replication in macrophages and CD4+ T cells from HIV controllers,” Blood, vol. 118, no. 4, pp. 955–964, 2011. [157] T. Miura, Z. L. Brumme, M. A. Brockman et al., “Impaired replication capacity of acute/early viruses in persons who become HIV controllers,” Journal of Virology, vol. 84, no. 15, pp. 7581–7591, 2010. [158] V. Avettand-Fenoel, T. Prazuck, L. Hocqueloux et al., “HIV- DNA in rectal cells is well correlated with HIV-DNA in blood in diﬀerent groups of patients, including long-term non- progressors,” AIDS, vol. 22, no. 14, pp. 1880–1882, 2008. [159] B. Ling, M. Mohan, A. A. Lackner et al., “The large intestine as a major reservoir for simian immunodeﬁciency virus in macaques with long-term, nonprogressing infection,” Journal of Infectious Diseases, vol. 202, no. 12, pp. 1846–1854, 2010. [160] J. J. Lefre`re, L. Morand-Joubert, M. Mariotti et al., “Even individuals considered as long-term nonprogressors show biological signs of progression after 10 years of human immunodeﬁciency virus infection,” Blood, vol. 90, no. 3, pp. 1133–1140, 1997. [161] H. Hatano, E. L. Delwart, P. J. Norris et al., “Evidence for persistent low-level viremia in individuals who control human immunodeﬁciency virus in the absence of antiretro- viral therapy,” Journal of Virology, vol. 83, no. 1, pp. 329–335, 2009. [162] F. Pereyra, S. Palmer, T. Miura et al., “Persistent low-level viremia in HIV-1 elite controllers and relationship to immu- nologic parameters,” Journal of Infectious Diseases, vol. 200, no. 6, pp. 984–990, 2009. [163] F. Pereyra, M. M. Addo, D. E. Kaufmann et al., “Genetic and immunologic heterogeneity among persons who control HIV infection in the absence of therapy,” Journal of Infectious Diseases, vol. 197, no. 4, pp. 563–571, 2008. [164] M. Lo´ pez, V. Soriano, A. Peris-Pertusa, N. Rallo´ n, C. Restrepo, and J. M. Benito, “Elite controllers display higher activation on central memory CD8 T cells than HIV patients successfully on HAART,” AIDS Research and Human Retro- viruses, vol. 27, no. 2, pp. 157–165, 2011.